The Insulin Resistance Intervention after Stroke (IRIS) trial showed that pioglitazone which improves insulin sensitivity could decrease the risk of AIS or myocardial infarction in nondiabetic patients with a recent transient ischemic attack (TIA) or AIS [10]. This evidence concerns the gene INS and transient ischemic attack.